Beijing Geyuantianrun Bio-tech Joins CPHI & PMEC China 2026 in Shanghai

    From June 16 to 18, 2026, the 24th CPHI China (World Pharmaceutical Ingredients China Exhibition) and the 19th PMEC China (World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition) grandly opened at the Shanghai New International Expo Centre.As an influential industry event covering the entire pharmaceutical industrial chain in Asia-Pacific, this exhibition covers an area of over 240,000 square meters, gathering more than 3,600 upstream and downstream pharmaceutical enterprises worldwide. It attracted over 110,000 professional buyers, R&D directors of pharmaceutical companies and foreign trade distributors from more than 150 countries across the globe to visit and negotiate cooperation.
Beijing Geyuantianrun Biotechnology Co., Ltd., a national high-tech enterprise, participated in the exhibition with its full range of high-purity animal-derived enzymes and core pharmaceutical API products, conducting in-depth exchanges with domestic and overseas pharmaceutical clients and reaching multiple cooperation intentions.

    At the exhibition booth, the company’s technical general manager and foreign trade team received visiting customers throughout the event. They gave detailed introductions to the proprietary separation and purification technology, stable production capacity and comprehensive export supporting solutions. With more than 20 years of experience in R&D and production of biochemical enzymes, the company’s products are exported to over ten countries and regions including Europe, America, Southeast Asia, Japan and South Korea, serving international pharmaceutical enterprises, CRO institutions and biological reagent manufacturers.Many overseas purchasers held in-depth discussions on bulk procurement of pharmaceutical-grade trypsin and RNase A as well as long-term OEM customization services. They highly recognized the company’s stable production capacity and stringent GMP production system.
 

    The global foreign trade market for biopharmaceuticals and pharmaceutical APIs is expanding continuously. As a key upstream raw material in the biopharmaceutical industrial chain, bioenzymes are seeing steady growth in market demand. As a vital platform for global pharmaceutical ingredient trade, CPHI China helps outstanding domestic biochemical enterprises expand into international markets.By taking part in this Shanghai exhibition, Geyuantianrun fully demonstrated the technical strength of domestic high-purity bioenzymes, and promoted customized process solutions for enzyme preparation production.

    According to the company’s management, it will keep increasing investment in R&D of enzyme purification technology, upgrade proprietary separation and purification equipment, and further expand production capacity for pharmaceutical-grade enzyme preparations. Relying on GMP-standard production lines and a sound global delivery system, the company will supply stable and cost-effective animal-derived protease APIs to pharmaceutical enterprises around the world, deepen cooperation across the global pharmaceutical industrial chain, and help domestic biochemical raw materials enter the international market.